Start free trial

Five minutes.
AI, made clearer.

A quiz, a dish, a password and a scan.

Read the briefing

Members read every story in the archive, re-verified. Sources and corrections stay open to everyone.

What the pen marks mean
  • rememberThe takeaway: what to remember
  • figureThe number that matters
  • evidenceThe evidence line
  • rulingThe ruling
  • claimThe claim that fails

Each mark is drawn once, as you reach it. Numbers are only circled when they come from the story’s own figures.

Microsoft's AI really did more than double doctors' accuracy in Science. The doctors were generalists working alone, the patients were simulated, and every author works for Microsoft.

A robot in a white coat wins a quiz show against a lone doctor while a hospital ward waits behind the curtain.
AI illustration

MAI-DxO scored 83.2% on hard NEJM cases against 36.1% for generalists with references. The authors say it shows nothing against specialists, teams or real clinics. A prospective test is only announced.

Members · 30 days free

See what the evidence actually shows.

Members read the full check on every story: what the evidence shows, why it matters to you and the one line to take with you. Every past edition, re-verified, and the Receipts Pack come with it. A$89 a year, about A$0.24 a day.

  1. At sign-up: 30 days free. Payment card required. One introductory trial per customer.
  2. Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
  3. You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.

By starting your trial, you agree to the Terms.

BS Killer is published by Inferno Tech Pty Ltd, ABN 27 647 413 474.

Open the evidence3 source pages

The claim we checked

MAI-DxO is more than twice as accurate as physicians using textbooks and the internet

These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.

microsoft.ai ↗
MAI-DxO is more than twice as accurate as physicians using textbooks and the internet
microsoft.ai ↗
Physicians achieved 22% without external reference resources and 36% with them, making MAI-DxO about 3.7 and 2.3 times more accurate, respectively.
microsoft.ai ↗
Benchmarks matter, but the true test is performance in real clinical environments.
microsoft.ai ↗
In a prospective study, patients will interact with the system directly, with performance measured against physicians’ independent assessments.
microsoft.ai ↗
Through a new partnership with Beth Israel Deaconess Medical Center in Boston, we will evaluate clinical reasoning capabilities across different hospital settings.
api.crossref.org ↗
outperforming generalist physicians (36.1 and 46.8%, respectively)
api.crossref.org ↗
Although these findings were obtained in a controlled benchmark setting
unite.ai ↗
The authors state that the comparisons do not show superiority over specialists, multidisciplinary teams, or real-world clinical practice
unite.ai ↗
A further stated limitation is the comparison against individual physicians rather than multispecialty collaboration
unite.ai ↗
conducted on 56 cases held out from engineering work
unite.ai ↗
averaging 22.3% accuracy closed-book at $3,049 per case and 36.1% open-book at $4,725
unite.ai ↗
achieved 83.2% accuracy at an average cost of $5,431 per case
unite.ai ↗
Cost-constrained configurations reached 80.9% accuracy at $2,241 and 79.6% at $1,303
unite.ai ↗
the authors state that all of them are Microsoft employees holding equity in the company
Open this check in the full collection →
The idea, illustrated01

Go inside the check.

    The full explanation appears when your reading access is confirmed.
    Next: Lab dish, not treatment

    The AI cancer 'treatment' is one plant compound that worked alongside an existing drug on cancer cell clumps in a dish. No mice, no patients yet.

    A scientist looks at a tiny lab dish while a crowd outside cheers a giant pill float.
    AI illustration

    UCLA's MAESTRO ranked 3,592 natural products. 23 of its 150 top picks showed synergy in lab spheroids, and berberine stood out. Animal studies are the next step, not the last.

    Members · 30 days free

    See what the evidence actually shows.

    Members read the full check on every story: what the evidence shows, why it matters to you and the one line to take with you. Every past edition, re-verified, and the Receipts Pack come with it. A$89 a year, about A$0.24 a day.

    1. At sign-up: 30 days free. Payment card required. One introductory trial per customer.
    2. Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
    3. You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.

    By starting your trial, you agree to the Terms.

    BS Killer is published by Inferno Tech Pty Ltd, ABN 27 647 413 474.

    Open the evidence3 source pages

    The claim we checked

    New AI unlocks a cancer treatment, and scientists are stunned

    These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.

    uclahealth.org ↗
    The researchers used the platform to evaluate 3,592 natural products for their potential to work with enzalutamide.
    uclahealth.org ↗
    a drug originally discovered and developed at UCLA that is commonly used to treat advanced prostate cancer
    uclahealth.org ↗
    The system identified 150 high-confidence candidates for testing in 3D prostate cancer spheroids.
    uclahealth.org ↗
    Of the 150 compounds tested, 23 showed evidence of synergy with enzalutamide
    uclahealth.org ↗
    Further testing identified berberine, a naturally occurring compound found in several plants, as a particularly promising candidate.
    uclahealth.org ↗
    The researchers plan to further evaluate the combination in patient-derived tumor models and animal studies.
    uclahealth.org ↗
    MAESTRO could substantially accelerate this process.
    uclahealth.org ↗
    berberine and enzalutamide showed consistent synergy across four prostate cancer models with different mechanisms of treatment resistance
    ebi.ac.uk ↗
    berberine-enzalutamide as an in vitro combination hit that re-sensitized resistant prostate cancer cells to AR blockade
    ebi.ac.uk ↗
    can prioritize and experimentally evaluate drug-combination hypotheses at an early stage of discovery.
    eutils.ncbi.nlm.nih.gov ↗
    This work introduces a hybrid in silico and in vitro lead discovery platform
    Open this check in the full collection →
    The idea, illustrated02

    Go inside the check.

      The full explanation appears when your reading access is confirmed.
      Next: Rogue, but customer-invited

      Banks found 'rogue' AI agents in customer accounts. Mostly, those are agents customers let in with their own passwords, and nobody published a count.

      A guard blocks a robot at a bank vault while its owner waves from behind it.
      AI illustration

      Axios says banks detect unauthorized agents and some appear to act on their own. The described case is customer-shared logins, there is no incident count, and the one named bank on record says it has seen none.

      Members · 30 days free

      See what the evidence actually shows.

      Members read the full check on every story: what the evidence shows, why it matters to you and the one line to take with you. Every past edition, re-verified, and the Receipts Pack come with it. A$89 a year, about A$0.24 a day.

      1. At sign-up: 30 days free. Payment card required. One introductory trial per customer.
      2. Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
      3. You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.

      By starting your trial, you agree to the Terms.

      BS Killer is published by Inferno Tech Pty Ltd, ABN 27 647 413 474.

      Open the evidence3 source pages

      The claim we checked

      US banks have detected rogue AI agents inside customer accounts and are moving to restrict access.

      These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.

      finance.yahoo.com ↗
      Major U.S. banks are detecting unauthorized third-party AI agents operating inside customer accounts
      finance.yahoo.com ↗
      some agents attempting to take actions that appear to be independent of user instructions, sources tell Axios.
      finance.yahoo.com ↗
      These are generally situations when an agent or AI assistant accesses a human's account with the user's permission and login credentials.
      finance.yahoo.com ↗
      Even if permitted by the user, this goes against the guidelines of most banks requiring that humans log in to their own accounts.
      finance.yahoo.com ↗
      contact call centers or appear to take actions independent of user instructions, the people said.
      finance.yahoo.com ↗
      hasn't observed instances of "rogue AI agents accessing our platforms."
      finance.yahoo.com ↗
      Many banks are broadly not able to parse whether agent account activity is user-directed, sources said.
      finance.yahoo.com ↗
      Morgan Stanley has begun blocking third-party agents from accessing its platforms
      pymnts.com ↗
      Charles Schwab CEO Rick Wurster said the brokerage is blocking unauthorized AI agents a double-digit number of times every week
      webull.com ↗
      Transcript: JPMorgan Chase Q3 2026 Earnings Conference Call
      webull.com ↗
      you don't want rogue agents, and there could be thousands of them.
      Open this check in the full collection →
      The idea, illustrated03

      Go inside the check.

        The full explanation appears when your reading access is confirmed.
        Next: 36 members, no outcomes

        The 42.9% is 36 people. All 84 in the study were screened at Biograph, and every author works for Biograph.

        A shopkeeper sticks red flags on his own customers through a magnifying glass.
        AI illustration

        Biograph's preprint used Caristo's FDA-authorised CaRi-Heart on 84 symptom-free adults. It counts flagged arteries, not heart attacks, and the press release smooths over one blood-test result.

        Members · 30 days free

        See what the evidence actually shows.

        Members read the full check on every story: what the evidence shows, why it matters to you and the one line to take with you. Every past edition, re-verified, and the Receipts Pack come with it. A$89 a year, about A$0.24 a day.

        1. At sign-up: 30 days free. Payment card required. One introductory trial per customer.
        2. Your trial ends 30 days after you start. Unless you cancel before then in Account → Manage subscription, we charge A$89 for the first year. It renews automatically at A$89/yr until cancelled.
        3. You can ask for a full refund within 14 days after any annual payment, renewals included, with no reason needed, by emailing [email protected]. This voluntary refund does not limit your rights under the Australian Consumer Law.

        By starting your trial, you agree to the Terms.

        BS Killer is published by Inferno Tech Pty Ltd, ABN 27 647 413 474.

        Open the evidence3 source pages

        The claim we checked

        AI analysis of CT scans finds 42.9% of patients have coronary inflammation

        These are quoted receipts, not a count of independent investigations. Several reports may rely on the same original source.

        medrxiv.org ↗
        Elevated FAI-Score (≥75th percentile) was present in 42.9% of participants (36/84; 95% CI 32.8% - 53.5%)
        medrxiv.org ↗
        84 consecutive asymptomatic adults (mean age 53.7 ± 8.6 years; 63.1% men) with no prior coronary artery disease underwent screening CCTA
        medrxiv.org ↗
        all authors (DS, JF, MN, MD) are employees of Biograph and may hold stock or stock options in the company
        medrxiv.org ↗
        received financial support from Biograph for the submitted work as employees of Biograph, which sponsored the study
        medrxiv.org ↗
        quantifies vascular inflammation and predicts cardiac mortality in symptomatic cohorts
        medrxiv.org ↗
        its prevalence, anatomical distribution, and clinical correlates in asymptomatic primary prevention populations remain uncharacterized
        medrxiv.org ↗
        Systemic hs-CRP (median 0.8 mg/L) exhibited an inverse correlation with maximum vessel FAI-Score (Spearman ρ=−0.27, p=0.014)
        biograph.com ↗
        The study, available to clinically eligible Biograph Black tier members
        biograph.com ↗
        showed no correlation with the presence of coronary inflammation and failed to identify which patients had inflamed arteries
        biograph.com ↗
        The study found that coronary inflammation is common (42.9%) in asymptomatic, low-risk adults
        hcplive.com ↗
        Caristo's De Novo submission drew on validation data from large independent populations published in The Lancet
        Open this check in the full collection →
        The idea, illustrated04

        Go inside the check.

          The full explanation appears when your reading access is confirmed.
          The finish line

          Edition complete

          You’re up to speed.

          That’s the 23 Oct 2026 briefing. Keep the useful bits. Leave the noise.

          Reading estimate: 785 words at 200 words per minute. Source quotes and the optional sections below add reading time.

          Get tomorrow's check in your inbox.

          One AI claim a night, checked against independent sources, receipts attached. Free.

          Free email updates. Unsubscribe any time.